{"organizations": [], "uuid": "8b228821c87928a7794d95978ea19b7690cc7f14", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180510.html", "section_title": "Archive News &amp; Video for Thursday, 10 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neurotrope-inc-on-may-4-neurotrope/brief-neurotrope-inc-on-may-4-neurotrope-bioscience-executed-a-services-agreement-with-worldwide-clinical-trials-idUSFWN1SH1NY", "country": "US", "domain_rank": 408, "title": "BRIEF-Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.056, "site_type": "news", "published": "2018-05-11T05:40:00.000+03:00", "replies_count": 0, "uuid": "8b228821c87928a7794d95978ea19b7690cc7f14"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neurotrope-inc-on-may-4-neurotrope/brief-neurotrope-inc-on-may-4-neurotrope-bioscience-executed-a-services-agreement-with-worldwide-clinical-trials-idUSFWN1SH1NY", "ord_in_thread": 0, "title": "BRIEF-Neurotrope Inc - On May 4 Neurotrope Bioscience Executed A Services Agreement With Worldwide Clinical Trials", "locations": [], "entities": {"persons": [{"name": "neurotrope", "sentiment": "none"}], "locations": [], "organizations": [{"name": "neurotrope inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "neurotrope bioscience executed a services", "sentiment": "negative"}, {"name": "brief-neurotrope inc", "sentiment": "negative"}, {"name": "neurotrope bioscience", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10 (Reuters) - Neurotrope Inc:\n* NEUROTROPE INC - ON MAY 4 NEUROTROPE BIOSCIENCE EXECUTED A SERVICES AGREEMENT WITH WORLDWIDE CLINICAL TRIALS\n* NEUROTROPE - DEAL RELATES TO SERVICES FOR CONFIRMATORY PHASE 2 STUDY OF BRYOSTATIN IN TREATMENT OF MODERATELY SEVERE TO SEVERE ALZHEIMERS DISEASE\n* NEUROTROPE INC - NEUROTROPE AND NEUROTROPE BIOSCIENCE EXPECT THAT FIRST STUDY SITE WILL BE INITIATED DURING Q2 OF 2018\n* NEUROTROPE INC - PER AGREEMENT TOTAL ESTIMATED BUDGET FOR SERVICES, INCLUDING PASS-THROUGH COSTS, IS APPROXIMATELY $6.9 MILLION Source text: ( bit.ly/2G2A8ww ) Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://bit.ly/2G2A8ww", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-11T05:40:00.000+03:00", "crawled": "2018-05-11T13:01:01.000+03:00", "highlightTitle": ""}